Tecentriq's Small-Cell Lung Cancer Success Takes Edge Off Roche's IO Position
Executive Summary
Roche's combination of Tecentriq with chemotherapy is ahead of rivals in first-line SCLC and has been filed with the US FDA.
You may also be interested in...
NICE Rejects Tecentriq For Small-Cell Lung Cancer In England
Roche’s Tecentriq has been rejected by health technology assessment body NICE for use in small-cell lung cancer on the National Health Service. The move follows an earlier knockback for the drug in PD L1-positive triple-negative breast cancer.
AstraZeneca Gets Fast Imfinzi Review For SCLC
The drug major has won a priority review for Imfinzi in small cell lung cancer from the FDA. If approved, the new indication could add $1bn to sales of the checkpoint inhibitor
Roche's Tecentriq Becomes Second In PD-1/L1 Family To Gain First-Line Lung Cancer Approval
The PD-L1 inhibitor's label excludes NSCLC patients with EGFR or ALK mutations, which could have been an advantage, but the indication largely reflects the registrational IMpower150 clinical trial's population.